Woodworth, T, Furst, DE, Alten, R, Bingham, C, Yocum, D, Sloan, V, ...
Objective. The OMERACT Drug Safety Working Group focuses on standardization of assessment and reporting of adverse events in clinical trials and longitudinal and observational studies in...
Zochling, JM, Grill, E, Alten, R, Ernst, J, Stucki, G, Braun, J
To identify the most relevant problems to be addressed in the multi-disciplinary care of patients with acute arthritis using focus groups of health professionals followed by a Delphi process. Methods...
Zochling, JM, Grill, E, Alten, R, Ernst, J, Stucki, G, Braun, J
To identify the most relevant problems to be addressed in the multi-disciplinary care of patients with acute arthritis using focus groups of health professionals followed by a Delphi process. Methods...
Woodworth, T, Furst, DE, Alten, R, Bingham, C, Yocum, D, Sloan, V, ...
Objective. The OMERACT Drug Safety Working Group focuses on standardization of assessment and reporting of adverse events in clinical trials and longitudinal and observational studies in...
Zochling, JM, Grill, E, Alten, R, Ernst, J, Stucki, G, Braun, J
To identify the most relevant problems to be addressed in the multi-disciplinary care of patients with acute arthritis using focus groups of health professionals followed by a Delphi process. Methods...
Braun, J., Baraliakos, X., Brandt, J., Listing, J., Zink, A., Alten, R., ...
Objective. Infliximab, a monoclonal antibody against tumour necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded...
Braun, J., Baraliakos, X., Brandt, J., Listing, J., Zink, A., Alten, R., ...
Objective. Infliximab, a monoclonal antibody against tumour necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded...
Braun, J., Baraliakos, X., Brandt, J., Listing, J., Zink, A., Alten, R., ...
Objective. Infliximab, a monoclonal antibody against tumour necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded...
Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis (2004)
Alten, R, Rovensky, J, Sloan, VS, Krammer, G, Kralidis, G, Richardson, P, ...
A randomised, double-blind study was performed to assess the efficacy and tolerability of lumiracoxib in patients with rheumatoid arthritis (RA). Patients received lumiracoxib 200 mg once daily...
Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis (2004)
Alten, R, Rovensky, J, Sloan, VS, Krammer, G, Kralidis, G, Richardson, P, ...
A randomised, double-blind study was performed to assess the efficacy and tolerability of lumiracoxib in patients with rheumatoid arthritis (RA). Patients received lumiracoxib 200 mg once daily...
Alten, R, Rovensky, J, Sloan, V, Krammer, G, Kralidis, G, Richardson, P, ...
Biomed Onderzoeksinst, Diepenbeek, Belgium. Schlosspk Klin, Berlin, Germany. Narodni Reumatol Ustav, Piestany, Slovakia. Novartis Pharmaceut Corp, E Hanover, NJ USA. Novartis Pharma AG, Basel,...
Alten, R, Rovensky, J, Sloan, V, Krammer, G, Kralidis, G, Richardson, P, ...
Biomed Onderzoeksinst, Diepenbeek, Belgium. Schlosspk Klin, Berlin, Germany. Narodni Reumatol Ustav, Piestany, Slovakia. Novartis Pharmaceut Corp, E Hanover, NJ USA. Novartis Pharma AG, Basel,...
Atopic disorders in ankylosing spondylitis and rheumatoid arthritis
Rudwaleit, M, Andermann, B, Alten, R, Sorensen, H, Listing, J, Zink, A, ...
Background: The prevalence of atopic disorders in ankylosing spondylitis (AS) is unknown. AS and rheumatoid arthritis (RA) exhibit divergent T helper (Th) cell cytokine patterns.
Alten, R, Gromnica-Ihle, E, Pohl, C, Emmerich, J, Steffgen, J, Roscher, R, ...
Background: Leukotriene B4 (LTB4) has a key role in the pathophysiology of rheumatoid arthritis (RA).
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis
Braun, J, Brandt, J, Listing, J, Zink, A, Alten, R, Burmester, G, ...
Objective: To obtain results of the second year extension of an original 3 month randomised, placebo controlled trial (and the 1 year extension study) assessing the use of infliximab, a monoclonal...